CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A

We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated...

Descripción completa

Detalles Bibliográficos
Autores principales: Stanchina, Michele, Pastore, Alessandro, Devlin, Sean, Famulare, Christopher, Stein, Eytan, Taylor, Justin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704571/
https://www.ncbi.nlm.nih.gov/pubmed/31439003
http://dx.doi.org/10.1186/s13045-019-0771-0
_version_ 1783445528794628096
author Stanchina, Michele
Pastore, Alessandro
Devlin, Sean
Famulare, Christopher
Stein, Eytan
Taylor, Justin
author_facet Stanchina, Michele
Pastore, Alessandro
Devlin, Sean
Famulare, Christopher
Stein, Eytan
Taylor, Justin
author_sort Stanchina, Michele
collection PubMed
description We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival.
format Online
Article
Text
id pubmed-6704571
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-67045712019-08-22 CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A Stanchina, Michele Pastore, Alessandro Devlin, Sean Famulare, Christopher Stein, Eytan Taylor, Justin J Hematol Oncol Letter to the Editor We tested whether a single nucleotide polymorphism (SNP) that affects splicing of CD33 predicted response to treatment in adults with acute myeloid leukemia (AML) who received the novel CD33 antibody-drug conjugate SGN-CD33A. This genotype, for the CD33 splice site SNP rs12459419, was not associated with clinical response (30% CR/CRi in both groups), event-free survival, or overall survival. BioMed Central 2019-08-22 /pmc/articles/PMC6704571/ /pubmed/31439003 http://dx.doi.org/10.1186/s13045-019-0771-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Letter to the Editor
Stanchina, Michele
Pastore, Alessandro
Devlin, Sean
Famulare, Christopher
Stein, Eytan
Taylor, Justin
CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title_full CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title_fullStr CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title_full_unstemmed CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title_short CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A
title_sort cd33 splice site genotype was not associated with outcomes of patients receiving the anti-cd33 drug conjugate sgn-cd33a
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6704571/
https://www.ncbi.nlm.nih.gov/pubmed/31439003
http://dx.doi.org/10.1186/s13045-019-0771-0
work_keys_str_mv AT stanchinamichele cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a
AT pastorealessandro cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a
AT devlinsean cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a
AT famularechristopher cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a
AT steineytan cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a
AT taylorjustin cd33splicesitegenotypewasnotassociatedwithoutcomesofpatientsreceivingtheanticd33drugconjugatesgncd33a

Ejemplares similares